TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07678931: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy

Sponsor: Chengdu Kangnuoxing Biopharma,Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 136 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,721,640

Rescue Site Savings

+$5,751,568

Unlock Full NCT07678931 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07678931 Rescue Dossier →